查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1601245

肺部疾病藥物市場：按藥物類別、按適應症、按藥物類型、按分銷管道、按最終用戶分類 - 全球預測 2025-2030

Pulmonary Drugs Market by Drug Class (Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines), Indication (Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease), Drug Type, Distribution Channel, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年肺病藥物市值為793.5億美元，預計2024年將達到861.4億美元，複合年成長率為8.03%，到2030年將達到1362.7億美元。

肺部疾病藥物市場包括多種旨在治療氣喘、慢性阻塞性肺病、肺動脈高壓和肺纖維化等呼吸系統疾病的藥物和治療方法。由於污染、吸菸率上升和人口老化等因素，全球呼吸系統疾病盛行率不斷上升，凸顯了對這些藥物的需求。這些治療主要包括支氣管擴張劑、皮質類固醇和生物製藥，並以多種方式給藥，包括吸入、口服和注射。確保有效管理這些疾病將改善患者的生活品質並減輕醫療保健系統的總體經濟負擔。隨著生技藥品、聯合治療和個人化醫療方法的引入，市場正在經歷重大進展。主要成長要素包括新興國家對呼吸照護的需求增加、向創新生物製藥的轉變以及政府促進呼吸健康的措施。最近的機會包括利用數位健康平台促進病人參與和依從性，以及探索藥物輸送系統中的奈米技術。公司可以透過利用與數位醫療提供者的合作夥伴關係並投資於研發來獲得優勢。然而，不斷上升的研發成本、嚴格的法律規範以及學名藥製造商的競爭給市場成長帶來了挑戰。也存在一些限制因素，例如獲得醫療保健的機會差異和保險報銷問題。創新可能集中在開發非侵入性給藥方法和新型藥物類別，以更有效地管理慢性呼吸道疾病。對基因療法和 CRISPR 技術的研究有望提供量身定做的治療解決方案。由於不斷的技術進步以及對更有效和更有針對性的治療方法的需求，肺病藥物市場的本質是競爭激烈和快節奏。企業應專注於維持創新能力，同時適應監管環境，以改善市場定位並抓住成長潛力。

主要市場統計
基準年[2023] 793.5億美元
預測年份 [2024] 861.4億美元
預測年份 [2030] 1362.7億美元
複合年成長率（%） 8.03%

市場動態：快速發展的肺部疾病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變肺病藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 解決肺部疾病流行問題並促進疾病治療和藥物獲取
    • 提高醫療費用和政府對肺病藥物的有利核准
  • 市場限制因素
    • 增加用於肺部疾病的藥物的召回
  • 市場機會
    • 開發治療肺部疾病的新型生技藥品和標靶藥物
    • 吸入藥物傳遞療法和技術的進展
  • 市場挑戰
    • 與藥物傳遞不當和抗藥性發展相關的限制

波特五力：駕馭肺部疾病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解肺部疾病藥物市場的外部影響

外部宏觀環境因素在塑造肺病藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解肺病治療藥物市場的競爭狀況

肺部疾病治療藥物市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 肺病藥物市場定位矩陣供應商績效評估

FPNV 定位矩陣是評估肺病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。四個象限清楚且準確地分類了供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 努力解決肺部疾病的流行問題並促進疾病治療和藥物獲取
      • 改善肺部疾病藥物的報銷和有利的政府核准
    • 抑制因素
      • 用於治療肺部疾病的藥物召回增加
    • 機會
      • 開發治療肺部疾病的新型生物製藥和標靶藥物
      • 吸入藥物傳遞療法和技術的進展
    • 任務
      • 與不適當的藥物傳遞和抗藥性發展相關的限制
  • 市場區隔分析
    • 藥物類別：合併藥物和單株抗體製劑的進展，為肺部疾病提供個人化治療
    • 適應症：需要有效的藥物來治療和管理慢性阻塞性肺病和囊腫纖維化
    • 藥物類型：治療肺部疾病的趨勢有利於具有成本效益的學名藥
    • 分銷管道：改善線上分銷策略，提高產品在患者和醫療保健提供者中的滲透率
    • 最終使用者：提供各種速效藥物來治療醫院的急性病例和嚴重呼吸道疾病。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依藥物類別分類的肺部疾病治療藥物市場

  • 抗膽鹼能藥
  • 抗白三烯
  • 抗組織胺藥
  • BETA2促效劑
  • 伴隨藥物
  • 單株抗體
  • 口服和吸入性皮質類固醇

第7章依適應症分類的肺部疾病治療藥物市場

  • 過敏性鼻炎
  • 氣喘
  • 慢性阻塞性肺病
  • 囊腫纖維化
  • 肺動脈高血壓

第8章依藥品類型分類的肺部疾病治療藥品市場

  • 學名藥
  • 處方藥

第9章肺部疾病治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第 10 章 肺部疾病治療市場：依最終使用者分類

  • 居家護理
  • 醫院
  • 專科診所

第11章 北美和南美肺部疾病治療市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太肺部疾病治療市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲肺部疾病治療市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Bridge Biotherapeutics 宣布獨立資料監測委員會對特發性肺纖維化 BBT-877 2a 期研究給予積極建議
    • 百時美施貴寶宣布美國FDA 授予臨床實驗LPA1 拮抗劑用於治療進行性性肺纖維化的突破性療法
    • 隨著氣喘專款的加速推進，Aiolos Bio 斥資 2.45 億美元啟動
    • Avalin 籌集 1.75 億美元資金用於開發 IPF 吸入器
    • Lupin 與 Mark Cuban 和慢性阻塞性肺病基金會 (COPD Foundation) 合作，擴大美國慢性阻塞性肺病 (COPD) 治療的可及性。
    • Apollo Therapeutics 籌集 2.265 億美元用於研究型藥物開發
    • Viatris 與 Quindeva 合作，宣布推出 Breina（Budesonide和Formoterol福莫特羅二水合物）吸入氣霧劑，這是 FDA核准的Symbicort非專利藥，用於治療氣喘和慢性阻塞性肺病患者
    • 美國FDA核准輝瑞疫苗「ABRYSVO」用於預防老年人呼吸道融合病毒（RSV）（RSV）
    • TFF 和 NIEHS 合作開發治療呼吸道疾病的粉末製劑
    • 美國FDA核准葛蘭素史克老年人呼吸道融合病毒（RSV）疫苗“Alexi”
    • Astra Zeneca推出新型氣喘治療藥物“Air Supra”
    • C4XD 與Astra Zeneca簽署 4.02 億美元協議，開發呼吸系統疾病治療藥物

公司名單

  • Pieris Pharmaceuticals, Inc.
  • Amgen Inc.
  • Novartis AG
  • Wellona Pharma
  • Icosavax, Inc.
  • Grifols, SA
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline PLC
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Sumitomo Pharma Co., Ltd.
  • F. Hoffmann-La Roche AG
  • Sun Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Vertex Pharmaceuticals Incorporated
  • Verona Pharma PLC
  • Johnson & Johnson Services, Inc.
  • Cipla Ltd.
  • Abbott Laboratories
  • Lupin Pharmaceuticals, Inc.
  • Mallinckrodt PLC
  • United Therapeutics Corporation
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Lung Therapeutics Inc.
  • Bayer AG
  • Bristol Myers Squibb Company
  • AstraZeneca PLC
  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Gilead Sciences, Inc.
  • Chiesi Farmaceutici SpA
Product Code: MRR-4316E4E893EF

The Pulmonary Drugs Market was valued at USD 79.35 billion in 2023, expected to reach USD 86.14 billion in 2024, and is projected to grow at a CAGR of 8.03%, to USD 136.27 billion by 2030.

The pulmonary drugs market encompasses a wide array of medications and therapies designed to treat respiratory diseases such as asthma, COPD, pulmonary hypertension, and lung fibrosis. The necessity for these drugs is underscored by the rising global prevalence of respiratory disorders attributable to factors like pollution, increasing smoking rates, and a growing aging population. These therapies primarily include bronchodilators, corticosteroids, and biologics, delivered through various modes like inhalation, oral or injectable administration. Ensuring effective management of these conditions enhances patients' quality of life and reduces the overall economic burden on healthcare systems. The market has seen significant advancements with the introduction of biologics, combination therapies, and personalized medicine approaches. Key growth influencers include an increasing demand for respiratory care in emerging economies, a shift towards innovative biologic drugs, and government initiatives promoting respiratory health. The latest opportunities include leveraging digital health platforms for patient engagement and adherence, and the exploration of nanotechnology in drug delivery systems. Companies can capitalize on partnerships with digital health providers and invest in R&D to stay ahead. However, market growth is challenged by high R&D costs, stringent regulatory frameworks, and competition from generic drug manufacturers. Limitations include disparities in healthcare access and reimbursement issues. Innovation could focus on developing non-invasive delivery methods and novel drug classes to manage chronic respiratory conditions more effectively. Research into gene therapy and CRISPR technology offers prospects for tailored treatment solutions. The nature of the pulmonary drugs market is highly competitive and fast-paced, driven by continuous technological advancements and the need for more effective, targeted therapies. Companies should focus on sustaining innovation capability while navigating regulatory landscapes to enhance market positioning and capture growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 79.35 billion
Estimated Year [2024] USD 86.14 billion
Forecast Year [2030] USD 136.27 billion
CAGR (%) 8.03%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pulmonary Drugs Market

The Pulmonary Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
    • Improvements in reimbursements and favorable government approvals for pulmonary drugs
  • Market Restraints
    • Increasing recall of drugs used for pulmonary conditions
  • Market Opportunities
    • Development of new biologics and targeted drugs for pulmonary disease treatment
    • Advancements in inhaled drug delivery therapies and technologies
  • Market Challenges
    • Limitations associated with improper drug delivery and development of drug resistance

Porter's Five Forces: A Strategic Tool for Navigating the Pulmonary Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pulmonary Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pulmonary Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pulmonary Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pulmonary Drugs Market

A detailed market share analysis in the Pulmonary Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pulmonary Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pulmonary Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Pulmonary Drugs Market, highlighting leading vendors and their innovative profiles. These include Pieris Pharmaceuticals, Inc., Amgen Inc., Novartis AG, Wellona Pharma, Icosavax, Inc., Grifols, S.A., Teva Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Viatris Inc., Dr. Reddy's Laboratories Ltd., Sumitomo Pharma Co., Ltd., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., Sanofi S.A, Vertex Pharmaceuticals Incorporated, Verona Pharma PLC, Johnson & Johnson Services, Inc., Cipla Ltd., Abbott Laboratories, Lupin Pharmaceuticals, Inc., Mallinckrodt PLC, United Therapeutics Corporation, Merck & Co., Inc., Pfizer Inc., Lung Therapeutics Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, AbbVie Inc., Boehringer Ingelheim International GmbH, Gilead Sciences, Inc., and Chiesi Farmaceutici S.p.A.

Market Segmentation & Coverage

This research report categorizes the Pulmonary Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Class, market is studied across Anti-Cholinergic Agents, Anti-Leukotrienes, Antihistamines, Beta-2 Agonists, Combination Drugs, Monoclonal Antibodies, and Oral & Inhaled Corticosteroids.
  • Based on Indication, market is studied across Allergic Rhinitis, Asthma, Chronic Obstructive Pulmonary Disease, Cystic Fibrosis, and Pulmonary Arterial Hypertension.
  • Based on Drug Type, market is studied across Generic Drugs and Prescription Drugs.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-User, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of pulmonary diseases and initiatives to promote disease treatment and drug accessibility
      • 5.1.1.2. Improvements in reimbursements and favorable government approvals for pulmonary drugs
    • 5.1.2. Restraints
      • 5.1.2.1. Increasing recall of drugs used for pulmonary conditions
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of new biologics and targeted drugs for pulmonary disease treatment
      • 5.1.3.2. Advancements in inhaled drug delivery therapies and technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations associated with improper drug delivery and development of drug resistance
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Class: Advancements in the formulations of combination drugs and monoclonal antibodies to offer personalized treatment of pulmonary diseases
    • 5.2.2. Indication: Need for effective drugs and medications to treat and manage COPD and cystic fibrosis
    • 5.2.3. Drug Type: Emerging preference for cost-effective generic medications for pulmonary disease management
    • 5.2.4. Distribution Channel: Improvements in online distribution strategies for better product penetration among patients and healthcare providers
    • 5.2.5. End-User: Availability of a versatile range of drugs with rapid onset action to address acute cases and severe respiratory disorders in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pulmonary Drugs Market, by Drug Class

  • 6.1. Introduction
  • 6.2. Anti-Cholinergic Agents
  • 6.3. Anti-Leukotrienes
  • 6.4. Antihistamines
  • 6.5. Beta-2 Agonists
  • 6.6. Combination Drugs
  • 6.7. Monoclonal Antibodies
  • 6.8. Oral & Inhaled Corticosteroids

7. Pulmonary Drugs Market, by Indication

  • 7.1. Introduction
  • 7.2. Allergic Rhinitis
  • 7.3. Asthma
  • 7.4. Chronic Obstructive Pulmonary Disease
  • 7.5. Cystic Fibrosis
  • 7.6. Pulmonary Arterial Hypertension

8. Pulmonary Drugs Market, by Drug Type

  • 8.1. Introduction
  • 8.2. Generic Drugs
  • 8.3. Prescription Drugs

9. Pulmonary Drugs Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Pulmonary Drugs Market, by End-User

  • 10.1. Introduction
  • 10.2. Homecare
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Pulmonary Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Pulmonary Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Pulmonary Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Bridge Biotherapeutics Announces Positive Recommendation from the Independent Data Monitoring Committee of the BBT-877 Phase 2a Study in Idiopathic Pulmonary Fibrosis
    • 14.3.2. Bristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
    • 14.3.3. Aiolos Bio Launches With USD 245 millions As Asthma-Focused Funding Accelerates
    • 14.3.4. Avalyn Raises USD 175 Million in Funding to Develop Inhaled IPF Drugs
    • 14.3.5. Lupin Partners With Mark Cuban and COPD Foundation to Expand Access to COPD Medication in the US
    • 14.3.6. Apollo Therapeutics Raises USD 226.5 million to Develop Medicines Based on Uni Research
    • 14.3.7. Viatris Announces Launch of Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the FDA-Approved Generic Version of Symbicort for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
    • 14.3.8. U.S. FDA Approves ABRYSVO, Pfizer's Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
    • 14.3.9. TFF and NIEHS Partner to Develop Powder Formulations for Respiratory Diseases
    • 14.3.10. US FDA Approves GSK's Arexvy, a Respiratory Syncytial Virus (RSV) Vaccine for Older Adults
    • 14.3.11. AstraZeneca Launches New Asthma Medication Called Airsupra
    • 14.3.12. C4XD and AstraZeneca Enter USD 402 million Deal to Develop Respiratory Disease Therapy

Companies Mentioned

  • 1. Pieris Pharmaceuticals, Inc.
  • 2. Amgen Inc.
  • 3. Novartis AG
  • 4. Wellona Pharma
  • 5. Icosavax, Inc.
  • 6. Grifols, S.A.
  • 7. Teva Pharmaceutical Industries Ltd.
  • 8. GlaxoSmithKline PLC
  • 9. Viatris Inc.
  • 10. Dr. Reddy's Laboratories Ltd.
  • 11. Sumitomo Pharma Co., Ltd.
  • 12. F. Hoffmann-La Roche AG
  • 13. Sun Pharmaceutical Industries Ltd.
  • 14. Sanofi S.A
  • 15. Vertex Pharmaceuticals Incorporated
  • 16. Verona Pharma PLC
  • 17. Johnson & Johnson Services, Inc.
  • 18. Cipla Ltd.
  • 19. Abbott Laboratories
  • 20. Lupin Pharmaceuticals, Inc.
  • 21. Mallinckrodt PLC
  • 22. United Therapeutics Corporation
  • 23. Merck & Co., Inc.
  • 24. Pfizer Inc.
  • 25. Lung Therapeutics Inc.
  • 26. Bayer AG
  • 27. Bristol Myers Squibb Company
  • 28. AstraZeneca PLC
  • 29. AbbVie Inc.
  • 30. Boehringer Ingelheim International GmbH
  • 31. Gilead Sciences, Inc.
  • 32. Chiesi Farmaceutici S.p.A

LIST OF FIGURES

  • FIGURE 1. PULMONARY DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. PULMONARY DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PULMONARY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PULMONARY DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-CHOLINERGIC AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTI-LEUKOTRIENES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PULMONARY DRUGS MARKET SIZE, BY BETA-2 AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PULMONARY DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PULMONARY DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ORAL & INHALED CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ALLERGIC RHINITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PULMONARY DRUGS MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PULMONARY ARTERIAL HYPERTENSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PULMONARY DRUGS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PULMONARY DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PULMONARY DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL PULMONARY DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL PULMONARY DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. PULMONARY DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. PULMONARY DRUGS MARKET, FPNV POSITIONING MATRIX, 2023